Cargando…
A randomized controlled trial of mycophenolate mofetil in patients with IgA nephropathy [ISRCTN62574616]
BACKGROUND: IgAN is the most common type of glomerulonephritis in the world. Between 15 and 40 percent of adults and children diagnosed with IgAN eventually progress to ESRD. Despite the need for effective treatment strategies, very few RCTs for IgAN have been performed. The most effective therapies...
Autores principales: | Hogg, Ronald J, Wyatt, Robert J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC415550/ https://www.ncbi.nlm.nih.gov/pubmed/15043759 http://dx.doi.org/10.1186/1471-2369-5-3 |
Ejemplares similares
-
Efficacy and safety of mycophenolate mofetil for IgA nephropathy: An updated meta-analysis of randomized controlled trials
por: Zheng, Jian-Nan, et al.
Publicado: (2018) -
Mycophenolate Mofetil for Severe IgA Vasculitis Nephropathy in Children: An Observational Study
por: Samsonov, Dmitry, et al.
Publicado: (2022) -
Mycophenolate mofetil therapy for steroid-resistant IgA nephropathy with the nephrotic syndrome in children
por: Kang, Zhijuan, et al.
Publicado: (2015) -
Efficacy and safety of mycophenolate mofetil treatment in IgA nephropathy: a systematic review
por: Chen, Youyuan, et al.
Publicado: (2014) -
Efficacy and safety of mycophenolate mofetil in patients with IgA nephropathy: an update meta-analysis
por: Du, Bing, et al.
Publicado: (2017)